** Shares of medical device maker Inspire Medical Systems INSP.N rise 5.4% to $185.49

** BofA Global Research upgrades stock to "buy" from "neutral", citing co has "turned the corner on profitability" with two straight quarters of positive margins and durable cost control

** INSP makes of non-invasive devices for patients with a common sleeping disorder, which works by stimulating the nerve that controls tongue muscles

** Brokerage also raises price objective on INSP from $220 to $255, representing premium of 44.8% to stock's last close

** Doctors expect INSP devices will continue to hold 84% market share even if rival devices from LivaNova LIVN.O and Nyxoah NYXH.BR are approved, brokerage says

** BofA says INSP has "good visibility in 2025 growth" and can achieve estimates of $950 mln in 2025 revenue

** 14 of 19 brokerages rate stock "buy" or higher and 5 "hold"; their median PT is $251 - LSEG data

** As of last close, stock down 13.5% YTD

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com;))